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Background: The Sodium Lowering in Dialysate (SoLID) trial is an ongoing a multi-center, prospective, randomised,
single-blind (assessor), controlled, parallel assignment clinical trial, enrolling 96 home and self-care hemodialysis
(HD) patients from 7 centers in New Zealand. The trial will evaluate the hypothesis that lower dialysate [Na+] during
HD results in lower left ventricular (LV) mass. Since it’s inception, observational evidence has suggested increased
mortality risk with lower dialysate [Na+], possibly due to exacerbation of intra-dialytic hypotension and subsequent
myocardial micro-injury. The Myocardial Micro-injury and Cardiac Remodeling Extension Study in the Sodium Lowering
In Dialysate Trial (Mac-SoLID study) aims to determine whether lower dialysate [Na+] results in (i) increased levels of
high-sensitivity Troponin T (hsTnT), a well-established marker of intra-dialytic myocardial micro-injury in HD populations,
and (ii) increased fixed LV segmental wall motion abnormalities, a marker of recurrent myocardial stunning and
micro-injury, and (iii) detrimental changes in LV geometry due to maladaptive homeostatic mechanisms.
Methods/design: The SoLID trial and the Mac-SoLID study are funded by the Health Research Council of New
Zealand. Key exclusion criteria: patients who dialyse > 3.5 times per week, pre-dialysis serum sodium <135 mM,
and maintenance haemodiafiltration. In addition, some medical conditions, treatments or participation in other
dialysis trials that contraindicate the study intervention or confound its effects, will be exclusion criteria. The
intervention and control groups will receive dialysate sodium 135 mM and 140 mM respectively, for 12 months.
The primary outcome measure for the Mac-SOLID study is repeated measures of [hsTnT] at 0, 3, 6, 9, and 12 months. The
secondary outcomes will be assessed using cardiac magnetic resonance imaging (MRI), and comprise LV segmental wall
motion abnormality scores, LV mass to volume ratio and patterns of LV remodeling at 0 and 12 months.
Discussion: The Mac-SoLID study enhances and complements the SoLID trial. It tests whether potential gains in
cardiovascular health (reduced LV mass) which low dialysate [Na+] is expected to deliver, are counteracted by
deterioration in cardiovascular health through alternative mechanisms, namely repeated LV stunning and micro-injury.
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The Sodium Lowering in Dialysate (SoLID) trial [1,2] is an
ongoing clinical trial to evaluate the hypothesis that redu-
cing sodium exposure in hemodialysis (HD) patients will
result in lower cardiovascular (CV) risk (www.solid.org.nz).
This hypothesis is based upon the substantial body of ob-
servational and clinical trial evidence that lowering dialysate
sodium concentration ([Na+]) improves blood pressure and
fluid overload, acceptance of left ventricular (LV) hyper-
trophy as a strong independent mortality risk [3], and an
assumption lower dialysate [Na+] should ameliorate LV
hypertrophy. The SoLID trial is a multi-center, prospective,
randomised, controlled clinical trial, enrolling 96 patients
from 7 centers. The intervention and control groups are
dialysed using dialysate [Na+] 135 mM and 140 mM re-
spectively, for 12 months. The primary outcome measure is
left ventricular mass index, as measured by cardiac MRI
after 12 months of treatment.
Since the design and inception of the SoLID trial, sev-
eral observational studies have suggested potential harm
from lower dialysate [Na+] in at-risk populations. The
most robust are from the Dialysis Outcomes and Prac-
tice Patterns Study (DOPPS) [4,5]. The first of these
studies reported that lower dialysate [Na+] (<137 mM)
was associated with a 35% higher mortality risk com-
pared to higher dialysate [Na+], but only in patients withFigure 1 Causal diagram relating low sodium dialysate during HD tolower serum [Na+]. The second study reported that
lower dialysate [Na+] was also associated with higher
hospitalization risk. Similar associations have been found
in other studies [6]. Of note, the authors of the DOPPS pa-
pers identified those patients with serum sodium < 137 mM
as having a discrete “frail” phenotype, with a higher propor-
tion of diabetes mellitus and CV disease.
Due to the observational nature of the studies, any
causal association between lower dialysate [Na+] and
increased mortality risk is speculative. However, the
studies do raise the possibility of harm, especially in frai-
ler patients. One possible causal mechanism involves
intra-dialytic hypotension (IDH), as shown in Figure 1.
IDH complicates 20-30% of HD sessions, and is more
likely to occur with lower dialysate [Na+] [7-9]. The reduc-
tion in myocardial perfusion pressure with IDH is com-
pounded by profound myocardial hypoperfusion that is
ubiquitous during HD, even in ostensibly ‘healthy’ dialysis
patients without a cardiac history or risk factors for CV dis-
ease [10,11]. Intra-dialytic myocardial stunning is common
in the myocardial regions with the greatest hypoperfusion,
and manifests as regional LV dysfunction. Repeated epi-
sodes of intra-dialytic myocardial stunning lead to regions
of fixed systolic dysfunction, probably as a result of under-
lying myocardial fibrosis [12]. It is therefore unsurprising
that IDH is strongly associated with myocardial stunningCVr mortality risk.
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is possible that any benefit from lower dialysate [Na+] con-
ferred by reducing inter-dialytic hypertension and LV mass
might be offset by increased episodes and severity of IDH
and subsequent myocardial stunning and micro-injury. HD
patients of the “frail” phenotype are likely to be most at risk
of harm from IDH because of their reduced coronary flow
reserve, and therefore to have a reduced threshold for
developing myocardial ischemia in the setting of reduced
coronary perfusion pressure [17-22].
This causal mechanism linking lower dialysate [Na+]
to poorer outcomes is only speculative, however, and
several clinical tenets argue against its validity. Firstly,
lower dialysate [Na+] is associated with lower inter-dialytic
weight gain (IDWG) [23-35] and consequently less fluid re-
moval during dialysis, factors which are protective against
IDH [36] . Secondly, elevation in plasma [Na+] is likely to
occur during treatment with a higher dialysate [Na+].
Elevation of plasma sodium by 1-3 mM within the normal
range is known to induceand “stiffening” of the vascular
endothelium independently of extra-cellular fluid volume
[37]. This is thought to be due to down- regulation of vaso-
dilatory nitric oxide formation, in the presence of higher
serum [Na+] [38,39]. Arterial stiffness reduces myocardial
perfusion, and reduces the threshold for myocardial
ischemia, especially in subendocardial regions for those
with LV hypertrophy [40,41]. Arterial stiffness may also
impair pressor responses to sympathetic activation
during fluid removal, and reduce capacity for appropri-
ate compensatory mechanisms during fluid removal
[42]. Finally, laboratory science has demonstrated that
increased sodium concentration can directly induce
cellular hypertrophy; hence, higher dialysate sodium it-
self may be an important determinant of myocardial
hypertrophy or LVH [43].
Overall, there is clinical equipoise around the use of
lower dialysate [Na+] and uncertainty with respect to
CV outcomes. The prime concern, however, is that there
could be potential harm from the intervention through
exacerbation of IDH and subsequent myocardial micro-
injury. Frequency of IDH is a secondary outcome in the
SoLID trial and is monitored by the trial’s Data Monitor-
ing Committee. However, these measurements alone are
unlikely to be sufficiently sensitive to detect or quantify
cardiac micro-injury. The Myocardial Micro-injury and
Cardiac Remodeling Extension Study in the Sodium
Lowering In Dialysate Trial (Mac-SoLID study) addresses
this shortcoming, and aims to determine whether lower
dialysate [Na+] results in (i) increased levels of high-
sensitivity Troponin T (hsTnT), a well-established
marker of intra-dialytic myocardial micro-injury in
HD populations [44-46], and (ii) increased fixed LV
segmental wall motion abnormalities, a marker of
recurrent myocardial stunning and cumulative micro-injury [12,13,46], and (iii) detrimental changes in LV geom-
etry due to maladaptive homeostatic mechanisms [47,48].
Methods/design
Study aim and hypothesis
Our hypothesis is that lower dialysate [Na+] during HD
is not unacceptably worse than standard care in causing
myocardial micro-injury (non-inferiority). The proposed
research will be conducted as an extension of the on-
going SoLID trial, a multi-center prospective, random-
ized, single-blind (outcomes assessor), active controlled,
parallel assignment 3-year clinical trial [1,2].
Primary aim
The Mac-SoLID study aims to compare the effect of low
dialysate [Na+] versus higher dialysate [Na+] during HD
on changes in [hsTnT] over one year.
Secondary aims
The Mac-SoLID study aims to compare the effect of low di-
alysate [Na+] versus higher dialysate [Na+] during HD on
 Changes in cardiac segmental wall motion over
one year.
 Changes in the LV geometry over one year.
Study design and setting
The SOLID Trial is enrolling 96 adult participants on
home and self-care HD from Waitemata, Auckland,
Counties Manukau, Waikato, Capital & Coast, Canter-
bury, and Southern District Health Boards (DHBs). The
rationale and protocol for the SoLID trial have been pre-
viously published [1,2]. There will be accrual of partici-
pants over 24 months, and a follow-up duration of
12 months. Participants will be randomly allocated to ei-
ther lower dialysate [Na+] of 135 mM or higher dialysate
[Na+] of 140 mM for 12 months duration, interventions
that represent poles of customary practice with respect
to dialysate [Na+] prescription in New Zealand.
Ethical considerations
Ethical approval for the SoLID trial and the Mac-SoLID
study has been obtained through the National (New
Zealand) Multi-region Ethics Committee (IRB00004663) of
the New Zealand Ministry of Health (IORG0000895), and
each institutional review board within participating DHBs.
(Waitemata FWA00003655, Auckland FWA00000503,
Counties Manukau FWA00021560, Waikato FWA00003
808, Capital & Coast FWA00002621, Canterbury FWA000
04799, Southern FWA00004456).
Target population and eligibility criteria
Eligibility criteria are: those on maintenance or self-care
home HD, age greater than 17 years; clinically suitable
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pre-dialysis plasma [Na+] ≥ 135 mM; willing to partici-
pate and able to provide consent.
Exclusion criteria are: HD at a frequency greater than
3.5 times per week; treatment with maintenance hemo-
filtration; life expectancy of less than 12 months;
scheduled for live donor kidney transplantation within
12 months of entry to the study; considered by the
treating nephrologist to have concomitant illnesses or
conditions that limit or contraindicate study procedures
and follow-up (e.g. frequent intra-dialytic hypotension
requiring fluid resuscitation, non-adherence); current en-
rolment in clinical studies involving anti-hypertensive
medications, changes in HD operating parameters, or any
other intervention that is likely to confound the outcome
of the trial; currently using sodium profiling during
haemodialysis treatments; documented infiltrative cardio-
myopathies (amyloid, glycogen storage disease), heredi-
tary cardiomyopathies (hypertrophic cardiomyopathy) or
moderate to severe aortic valve disease (aortic stenosis,
regurgitation).Recruitment of participants
The usual recruitment practice for the SoLID trial, pre-
viously published [1,2], will continue. Participant infor-
mation and consent forms will be updated to include the
two additional end-point measures that comprise the
Mac-SoLID study. Those participants who are already
enrolled or have already completed the SoLID trial will
be informed of the Mac-SoLID study. They will be asked
to sign an extra consent form agreeing to [hsTnT] being
tested on their stored serum and an additional analysis
of their cardiac MRIs by the trial cardiologists.Randomization
In the SoLID trial, those eligible after baseline assessment
are randomly assigned to lower and higher dialysate [Na+]
by a computer generated sequence in blocks of 4 partici-
pants. Randomization is stratified by a) treating center, and
b) conventional (≤18 hours/week) versus extended-hour
(>18 hours/week) HD.Blinding
Two blinded independent analysts will analyze all
cardiac MRI data, and the results will be reconciled in
accordance with the standard operating procedures of
the group. Both analysts will be monitored weekly for
drift.
Serum samples will be frozen and stored until the end
of the trial when [hsTnT] analysis will be undertaken in
a single batch, at a single laboratory. Individual samples
will be de-identified.Interventions
Apart from dialysate [Na+], HD operating parameters
for all participants will be managed in usual fashion ac-
cording to local treatment goals. Dietary salt intake will
be managed according to local clinical practice guidelines
(Nutrition & Dietetics 2006; 63 (Suppl. 2): S35–S45), and
monitored at baseline and 6-monthly using 3-day food diar-
ies. Residual urinary Na + excretion will be monitored at
baseline and 6-monthly using inter-dialytic urine collection.
Lower dialysate [Na+] HD
This group will undergo HD with dialysate [Na+] of
135 mM for a duration of one year, introduced grad-
ually by changes of 1 mmol/week over a 4-week run-in
period. BP will be optimized by changes to target
weight and antihypertensive medications according to
a standardized protocol.
Higher dialysate [Na+] HD
This group will undergo HD with dialysate [Na+] of
140 mM for a duration of one year, similarly introduced
by changes of 1 mmol/week over an appropriate run-in
period. BP will be optimized according to the standard-
ized protocol above.
Research outcomes and endpoints
Primary outcomes measure - high-sensitivity Troponin T
The primary end-point is time averaged [hsTnT], which
will be measured at 3, 6, 9, and 12 months. [hsTnT] will be
measured using the 4th generation Roche hsTnT assay
(Elecsys), which will be performed on frozen serum samples
which are being drawn at each time point. Samples will be
drawn immediately prior to HD after a “long break”.
Secondary outcomes measures
Segmental wall motion (SWM)
The first secondary end-point is SWM (score in units) at
12 months. SWM will be measured using cardiac MRI
studies performed prior to HD treatments after a “long
break”. All cardiac MRI studies will be performed in the fol-
lowing local centers according to a standardized protocol:
The Centre for Advanced MRI (CAMRI) at the University
of Auckland (www.mri.auckland.ac.nz), Valley Imaging and
X-ray at Hutt Valley DHB, Midland MRI, Christchurch
Hospital, and Dunedin Hospital. Assessment of LV function
and wall motion will be performed on trueFISP cine im-
aging (6–7 short axis and 3 LV long axis with 20–30 cardiac
phases depending on heart rate). Analysis of the images will
be performed at a core laboratory at the Auckland MRI Re-
search Group, University of Auckland, New Zealand. Each
patient will have a four-dimensional mathematical model of
the left ventricle created using guidepoint fitting. In all
cases, volume, mass and wall thickness will be measured
directly from the moving 3D curved surfaces, which track
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been validated for global parameters such as LV mass, end-
diastolic volume, end-systolic volume, stroke volume and
ejection fraction using global gold standard model. Seg-
mental wall motion analysis will be assessed according to a
standard 17-segment model [49,50]. Each segment will be
analyzed individually and scored on the basis of motion
and systolic thickening and a wall motion score index will
be derived. All data will be analyzed in duplicate by two
blinded analysts.
Left ventricular geometry
The second secondary end-point is an assessment of LV
geometry at 12 months. LV hypertrophy is the primary
outcome of the SoLID trial, and well established as a
powerful, independent predictor of CV morbidity and
mortality among dialysis patients. Abnormal LV remod-
eling also carries an incremental risk independent of LV
hypertrophy, particularly in studies of individuals free of
cardiovascular disease (Cheng et al. Circ Cardiovasc Im-
aging 2009; 2:191–198) [51-55]. Cardiac remodeling can
be described as a physiologic and pathologic condition
that may occur after myocardial infarction, pressure or
volume overload, inflammatory heart muscle disease, or
idiopathic dilated cardiomyopathy. The exact cellular
and molecular pathways responsible for LV remodeling
are still unclear, although a key event is myocyte length-
ening and stretch, stimulated expression of altered pro-
teins and myocyte hypertrophy, leading to a further
deterioration in cardiac performance and increased neu-
rohormonal activation. In addition, a parallel process of
increased activation of aldosterone and cytokines may
also stimulate collagen synthesis, thus leading to fibrosis
and remodeling of the extracellular matrix [47].
Three abnormal LV geometric patterns have been de-
fined: concentric hypertrophy, eccentric hypertrophy,
and concentric remodeling [55,56]. Each pattern appears
to carry a different risk for CV events [57,58]. LV re-
modeling analysis will include an assessment of LV end-
diastolic volume, LV mass, and mass to volume [M-V]
ratio (unadjusted LV mass/LV end-diastolic volume ra-
tio). Classification of LV geometry by echocardiography
relies on measurement of relative wall thickness, and the
M-V ratio is accepted as the cardiac MRI equivalent of
relative wall thickness. The M-V ratio, however, lacks a
well-defined normal reference range, and distributions
that have been determined from healthy volunteers with-
out co-existent coronary artery disease, hypertension, or
other forms of congestive heart disease/fluid overload
may not apply to those on dialysis. Accordingly, classifi-
cation of patients into the three abnormal LV geometric
patterns in this Mac-SoLID study will be based on distribu-
tions within the study population, rather than arbitrary
partition values for M-V ratio from the literature.Other outcome measures in the SOLID trial
Left Ventricular mass index and volumes (measured using
cardiac MRI at 12 months), Left Ventricular haemodynam-
ics (assessed by N-terminal of the prohormone brain natri-
uretic peptide and Urotensin II levels at 3, 6, 9, and
12 months), extracellular fluid volume (assessed by bioim-
pedence spectroscopy at 3, 6, 9, and 12 months), blood
pressure (assessed by (a) intra-dialytic BP and (b) inter-
dialytic BP measured as ambulatory recordings at 0, 6, and
12 months), arterial stiffness (assessed by carotid-femoral
Pulse Wave Velocity at, 6, and 12 months and by radial
Pulse Wave Analysis at 3, 6, 9 and 12 months, thirst and
xerostomia (measured using validated inventories at 3, 6, 9,
and 12 months), intra-dialytic hypotension (assessed as a
summary measure from the preceding interval at 3, 6, 9,
and 12 months), inter-dialytic weight gain (assessed as a
summary measure from the preceding interval 3, 6, 9, and
12 months) health-related quality of life (measured by the
KDQOL® and EuroQol EQ-5D questionnaires at 0 and
12 months), long-term CV mortality risk (assessed by high
sensitivity C-reactive protein levels 3, 6, 9, and 12 months),
pre-dialysis serum ionic activity (γNa) (3, 6, 9, and
12 months).
All measures corresponding to outcomes will also be
recorded at baseline (0 months).
Monitoring for adverse events
A formal Data Monitoring Committee (DMC) consti-
tuted by the New Zealand Health Research Council Data
Monitoring Core Committee is monitoring the safety
and conduct of the SoLID trial according to the terms of
its charter. An independent study statistician and data
manager generate both the open and closed Reports for
the DMC, and have no connection to the clinical aspects
of the trial. Safety reports are made and reviewed by the
DMC on a 6 monthly basis.
The Mac-SoLID Extension Trial has the same inter-
vention and study population, and will be therefore sub-
ject to the same monitoring.
Analysis populations
For analysis of data, we define Intention to Treat (ITT)
and Per Protocol (PP) analysis sets. The ITT set consists
of all randomized participants who have at least one
baseline measurement. All participants in the ITT set
will be analyzed in the group to which they were allo-
cated, even if they do not receive the allocated treat-
ment, do not commence treatment, change dialysis
modality or receive at kidney transplant, are lost to
follow-up, or die thereby preserving the intention-to-
treat framework. In particular, titration failures will re-
main within the ITT population as participants.
The PP analysis set consists of participants that fulfill
criteria for the ITT set, have complete primary endpoint
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violations during the study. Average [hsTnT] is consid-
ered complete if at least one follow-up measurement is
available. The following describes the major protocol
deviations that will exclude patients from the PP popula-
tion (minor deviations will not do so): eligibility viola-
tion; absence of any efficacy data, titration failure; other
major violations will be identified by the DMC of the trial
during the study and/or during the data review process.
The list of all protocol deviations will be reviewed by the
DMC who will determine the degree of the violation
(i.e. major versus minor). Protocol deviations considered as
minor will not lead to excluding patients from the PP
population for analysis.
Statistical analysis
For the primary (non-inferiority) outcome, primary analyses
will be carried out on the PP analysis set, to promote con-
servative inference. For the secondary (superiority) out-
comes, primary analyses will be done on the ITT set.
Non-inferiority tests will be carried out against one-
sided alternatives, superiority tests against two-sided al-
ternatives. All tests of significance of hypotheses con-
cerning treatment effect parameters will be carried out
using a significance level of 5%. All estimates will be
produced as point estimates and as 95% confidence
intervals. Per comparison error rate (PCER) control will
be used in all analyses, with the exception of some sub-
group analyses where False Discovery Rate (FDR) con-
trol will be implemented.
Blind review
Prior to unblinding, all outcome data will be reviewed
by an independent statistician to determine whether a
transformation, further transformation or alternative
generalised linear model is necessary (for continuous co-
variates); whether efficiency-improving covariates should
be included in the analyses; and whether the missing
data strategy appears adequate. Normality assessment
will follow usual visual assessments and normality tests.
Candidate covariates for inclusion will be those with
wide (>1 pooled standard deviation) separation at base-
line, and those identified through experience or litera-
ture searches by the (blinded) investigative team as
being potentially important to explain variability. They
will be retained for adjustment if they clearly improve
the model in terms of the coefficient or adjusted coeffi-
cient of determination, in the absence of knowledge re-
garding treatment.
Primary outcome – [hsTnT]
Measurements from the primary outcomes will be treated
in a repeated measures format and assigned weights to
maintain the time-averaged interpretation of the finalresults (equal weights in the case of complete data).
Measurements will be logarithmically transformed
based on evidence from the pilot data A weighted
linear mixed model will be used to produce a treatment
contrast, adjusted for baseline and any covariate identi-
fied in the blind review, appropriate to the time-averaged
outcome.
Secondary outcome – SVM and LV geometry
For both secondary outcomes, we will undertake univar-
iate (single outcome) endpoint analysis of the measure-
ments at 12 months. We will use analysis of covariance
(ANCOVA) to estimate the treatment effect, adjusting
for baseline and potentially adjusting for covariates iden-
tified in the course of the blind review. The resulting
treatment contrast will be reported as a point estimate
and as a 95% confidence interval.
Contingency for non-normality
Equivalent analyses after a normalising data transform-
ation will be carried out if non-normality of outcomes is
evinced. The choice of transformation will be guided by
the stabilisation of variance. When a transformation is
applied, location estimates and confidence intervals will
be transformed back to the original scale, with first-
degree bias correction.
Missing data
Every effort will be made to minimise missing data.
Missing outcome data will cause the patient/time point
instance to be removed from the analysis. In the case of
time-averaged endpoints, non-missing data will be ap-
propriately reweighted. Joint modelling of missingness
and the primary outcome will be carried out, for sensi-
tivity assessment, if missingness exceeds 10% or is sig-
nificantly different between the intervention arms at the
5% level.
Subgroup analyses
Subgroup analyses will be performed for the primary out-
come and time-averaged BP (intra-dialytic, inter-dialytic,
percentage maximum recommended daily dose of antihy-
pertensives) according to the baseline severity of LV hyper-
trophy, baseline severity of hypertension, and baseline
pre-dialysis plasma ionic [Na+] activity. Subgroup analyses
will be carried on using interaction of the groups thus
defined and the treatment arms.
Power calculations
The statistical power calculations for the primary
outcome are based on the non-inferiority hypothesis
that lower dialysate [Na+] HD sodium is does not
induce markedly higher [hsTnT] levels than the higher
dialysate [Na+].
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as markers for important and detectable myocardial
micro-injury in this population [44,46]. For sample size
estimation purposes, we retained a baseline-proportional
increase of [hsTnT], and an increase of the probability
of achieving [hsTnT] > 60 ng/L. In the former case,
doubling of the baseline has been identified as a clinic-
ally meaningful difference. We use a relative maximal
increase of 50% to define non-inferiority. In the latter
case we set a relative increase of 1/3 as the threshold for
inferiority.
We determined a target sample size in consideration
of these two criteria, to achieve a power of 80% to de-
clare non-inferiority, viewed as a one-sided alternative at
a 5% significance level [59]. For sample size consider-
ations, we used published literature employing the 4th
generation Roche hsTnT assay (Elecsys) [44]. Baseline
[hsTnT] were obtained from a NZ study of HD patients
using the same assay [60].Accordingly, we assumed the
mean and within-group standard deviation for [hsTnT]
to be 118 and 291 ng/L respectively, with an overall
correlation between baseline and follow-up value at
3 months of 0.268. We assumed the proportion of pre-
dialysis [hsTnT] >60 ng/L to be 0.52 at baseline. For
both the [hsTnT] value and [hsTnT] thresholding ap-
proaches, we calculated sample size using Monte Carlo
simulation and mixed effects modelling adjusting for
baseline value (on the log scale). Based on the original
assumptions in the SOLID Trial, we allowed 25% for
drop-outs.
Using a margin of non-inferiority defined by an indi-
vidual relative average increase of baseline [hsTnT] of
50% or more requires a target of 33 participants per arm
to achieve 80% power. This corresponds to the planned
primary analysis. Using a margin defined by a relative in-
crease of 1/3 in the probability of a participant having
time-averaged [hsTnT] superior to 60 ng/L (correspond-
ing to an increase of 17 percentage points) yields a target
of 31 participants per arm to recruit to achieve the same
power.
Discussion
The SoLID trial is the first randomized controlled trial
to investigate the effect of lower dialysate [Na+] upon
LV structure and function, and is now close to comple-
tion. The outcomes of this research will provide defini-
tive evidence about the efficacy of lower dialysate [Na+]
to improve CV outcomes in HD populations. The SoLID
trial will also provide data on important patient-centered
outcomes, such as the effect of lower dialysate [Na+] on
thirst, xerostomia, HRQoL and intra-dialytic hypotension.
If the benefit of lower dialysate [Na+] is confirmed, other
benefits might also flow on from reduced CV morbidity
and mortality, including improvements in lower healthresource consumption and less societal burden of treat-
ment. Operationally, lower dialysate [Na+] is a simple and
cost-free intervention, and for appropriate dialysis popula-
tions it can easily be implemented on a large-scale.
The Mac-SoLID trial enhances and complements the
SoLID trial. It will provide reassurance that the potential
gains in cardiovascular health (reduced LV mass), which
lower dialysate [Na+] is expected to deliver, are not off-
set by deterioration in cardiovascular health through
alternative mechanisms, namely repeated LV stunning
and micro-injury. The information forthcoming from
the Mac-SoLID trial may also help us to better pinpoint
those patients who fit the “frail” phenotype and are
inherently unsuitable for dialysis treatment with lower
dialysate [Na+].
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